Business
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
-- RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June
About this update from Rallybio Corporation
[{"type":"text","content":"\n-- RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 --\n\n\n-- RLYB212 Phase 1 Multiple Dose Cohort Study Results Expected in 4Q 2023 --\n\n\n-- Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study Including Safety, PK and PD Expected in 4Q 2023 --\n\n\n-- $137.8 million cash, cash equivalents and marketable securities as of June 30, 2023; Provides Runway into 1Q 2025 --\n\n\n NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB) today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent program and corporate developments.\n\n\n“We continue to make significant progress across our portfolio. We were pleased to have results from the Phase 1b proof-of-concept study for RLYB212, our anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), presented at the International Society on Thrombosis and Haemostasis Congress in June. With both dose groups in the study meeting the proof-of-concept criteria of at least 90% reduction in mean platelet elimination half-life, these results continue to support the potential use of subcutaneous RLYB212 for the prevention of HPA-1a alloimmunization and FNAIT. In the fourth quarter of 2023, we plan to complete the toxicology program for RLYB212, and share the results from the multiple dose cohort of our ongoing Phase 1 study for RLYB212. In parallel, we expect to initiate regulatory discussions which will support the initiation of a Phase 2 dose confirmation study in pregnant women at higher risk of FNAIT for RLYB212 in the second half of 2024,” said Stephen Uden, M.D., Chief Executive Officer of Rallybio.\n\n\nDr. Uden continued, “We continue to advance our multiple ascending dose Phase 1 study of RLYB116, an inhibitor of complement component 5 (C5) and expect to share initial data from this study, as well as details on our initial indication strategy for RLYB116, in the fourth quarter of 2023. As we continue to fortify our position as a leader in the development of transformative medicines for underserved rare diseases, we believe our existing capital will allow us to advance our portfolio through upcoming milestones.”\n\n\nMaternal Fetal Blood Disorders\n\n\nR...